newsPositive Phase II results for CNS drug neflamapimod7 October 2020 | By Hannah Balfour (European Pharmaceutical Review)Neflamapimod taken three times a day significantly improved cognition in trial participants with mild-to-moderate dementia with Lewy bodies (DLB).